CureVac, the latest experimental coronavirus vaccine, proves just 48 percent effective overall, a disappointing result
The vaccine is the third to be based on messenger RNA technology that is part of the Pfizer-BioNTech and Moderna vaccines.
View original article
Contributor: Carolyn Y. Johnson
